Formulary
Linagliptin: Indications, Dosing, Side Effects and Interactions
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
MedNext Academy | 3 min read
Linagliptin: Indications, Dosing, Side Effects and Interactions
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Drug action
Inhibits dipeptidylpeptidase-4 to increase insulin secretion and lower glucagon secretion.
Indications and dose
**Type 2 diabetes mellitus as monotherapy (if metformin inappropriate), or in combination with other antidiabetic drugs (including insulin) if existing treatment fails to achieve adequate glycaemic control**
- **Adult** (By Mouth): 5 mg once daily, for further information on use with other antidiabetic drugs-consult product literature.
Cautions
History of pancreatitis
Side effects
Cough; nasopharyngitis Rare or very rare Angioedema; bullous pemphigoid (discontinue); skin reactions Frequency not known Pancreatitis Side-effects, further information Discontinue if symptoms of acute pancreatitis occur such as persistent, severe abdominal pain.
Interactions
**Other interactions (24):**
- Pharmacodynamic interactions Insulin and sulphonylureas Insulin and sulphonylureas may increase the risk of hypoglycaemia.
- Therefore, a lower dose of insulin or sulphonylureas may be required to reduce the risk of hypoglycaemia when used in combination with Glyxambi (see sections 4.2, 4.4 and 4.8).
- Diuretics Empagliflozin may add to the diuretic effect of thiazide and loop diuretics and may increase the risk of dehydration and hypotension (see section 4.4).
- Pharmacokinetic interactions Effects of other medicinal products on empagliflozin Empagliflozin is mainly excreted unchanged.
- The effect of UGT induction on empagliflozin (e.g.
- Co-treatment with known inducers of UGT enzymes is not recommended due to a potential risk of decreased efficacy of empagliflozin.
Pregnancy
Avoid-no information available.
Breast feeding
Avoid-present in milk in animal studies.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Linagliptin in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

